Replies to post #251651 on Biotech Values

[DewDiligence]

NVO 1Q24 sales for T2D/obesity drugs:

https://ml-eu.globenewswire.com/Resource/Download/01af84ed-a119-435a-9553-ddd08340ba2d

• Ozempic $3.9B, +43% YoY in constant currency

• Wegovy $1.3B, +107% YoY in constant currency

• Rybelsus $0.7B, +17% YoY in constant currency

Note: Ozempic and Wegovy are the same drug (at different recommended doses) for T2D and obesity, respectively. Rybelsus is an oral formulation of the same drug approved for T2D.